Onconic Therapeutics온코닉테라퓨틱스
476060 · KOSDAQ · ₩476060 · 온코닉테라퓨틱스
₩12,620▼ ₩450 (3.44%)End-of-day · Oct 29, 2026 · End-of-day prices.
Filings
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Oct 16, 2026Open on DART
Predicted impact: Low
Record date setting is routine and tied to the already announced shareholders' meeting.
- Shareholders' meeting called주주총회소집결의 (임시주주총회)Oct 16, 2026Open on DART
Predicted impact: Low
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Oct 16, 2026Open on DART
Predicted impact: Low
- Notice of shareholders' meeting주주총회소집공고Oct 16, 2026Open on DART
Predicted impact: Low
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Sep 3, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)(자스타프라잔시트르산염) 기반 삼제요법의 헬리코박터 파일로리 양성 환자 대상 유효성 및 안전성 평가를 위한 제3상 임상시험계획승인(변경승인))Sep 2, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 12, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (자큐보정(JP1366)(자스타프라잔시트르산염)의 약물상호작용 확인을 위한 제1상 임상시험 결과)Jul 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 3, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)의 미란성 위식도역류질환 치료 후 유지요법에 대한 제3상 임상시험계획승인(변경승인))Jul 2, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 12, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정(JP1366)(자스타프라잔시트르산염) 기반 삼제요법의 헬리코박터 파일로리 양성 환자 대상 유효성 및 안전성 평가를 위한 제3상 임상시험계획승인(변경승인) 신청)Jun 10, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (자큐보구강붕해정(JLP-2302)의 비위관투여 시 약동학 및 안전성 비교 평가를 위한 제1상 임상시험계획승인(변경승인))Jun 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정(JP-1366)(자스타프라잔시트르산염) 기반 삼제요법의 헬리코박터 파일로리 양성 환자 대상 유효성 및 안전성 평가를 위한 제3상 임상시험계획승인(변경승인) 신청)Jun 1, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보구강붕해정(JLP2302)(자스타프라잔시트르산염)의 비위관투여 시 약동학 및 안전성 비교평가를 위한 제1상 임상시험계획승인(변경승인)신청)May 11, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 11, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 6, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Apr 22, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 17, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 17, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 13, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 10, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (자큐보정(JP-1366)의 미란성 위식도역류질환 치료 후 유지요법에 대한 제3상 임상시험)Mar 31, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 23, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 23, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 23, 2026Open on DART
- Audit report submitted감사보고서제출Mar 13, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (네수파립(JPI547)의 음식물 영향 및 인종 간 차이 확인을 위한 제1상 임상시험계획승인(변경승인))Mar 9, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 6, 2026Open on DART
- [Amended] Change of 30% or More in Sales or Profit Structure (15% or More for Large Companies)[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동Mar 6, 2026Open on DART
- [Amended] Change of 30% or More in Sales or Profit Structure (15% or More for Large Companies)[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동Mar 6, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 6, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 6, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Mar 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 26, 2026Open on DART
- Outlook on Business Performance (Fair Disclosure)영업실적등에대한전망(공정공시)Feb 5, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인) (네수파립(JPI-547)의 난소암 제2상 임상시험계획승인(변경승인))Jan 20, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 19, 2026Open on DART
- Trading Plan Report for Executives and Major Shareholders' Specific Securities임원ㆍ주요주주특정증권등거래계획보고서Jan 19, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 15, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jan 12, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 9, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 9, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 6, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 6, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 24, 2025Open on DART
- [Amendment] Business Performance Outlook (Fair Disclosure)[기재정정]영업실적등에대한전망(공정공시)Dec 23, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Onconic Therapeutics / 온코닉테라퓨틱스 / 476060 / KRX:476060
Source: KRX statistical information